Marijuana Use for MS Linked to Legal Permissiveness
Cannabis use among patients with multiple sclerosis is more likely where cannabis laws are more permissive.
Treatments
FDA Approves Ubrogepant Tablets for Acute Treatment of Migraine
The Food and Drug Administration (FDA) has approved Ubrelvy (ubrogepant tablets; Allergan), the first oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine with or without aura in adults. The approval was supported by two pivotal phase 3, randomized, double-blind, placebo-controlled trials (ACHIEVE I and ACHIEVE II) that evaluated the efficacy,…
Headache and Migraine: Short- and Long-Term Effects of Medical Cannabis
The aim of this study was to determine whether inhalation of cannabis decreases headache and migraine rating and whether sex, type of cannabis (concentrate vs flower), THC, CBD, or dose are contributing factors to changes in these ratings.
Shift in Prescribing Patterns for Migraine Prophylaxis With the Emergence of Anti-CGRP Antibodies
Results of a survey on early prescribing patterns of emerging treatments for migraine prophylaxis indicate that clinicians anticipate decreased use of onabotulinumtoxinA and increased use of erenumab for episodic migraine treatment.
Noninvasive Vagus Nerve Stimulation Effective for Cluster Headache
Researchers pooled data from 2 randomized, double-blind, placebo-controlled trials and found that noninvasive VNS is effective in aborting attacks in episodic cluster headache.
Limited Evidence Supporting Effectiveness of Cranial Electrical Stimulation for Chronic Pain
Researchers reviewed evidence relating to the benefits and harms of cranial electrical stimulation for adults with chronic painful conditions, depression, anxiety, and insomnia.
Lomerizine Treatment May Increase Interictal Regional Cerebral Blood Flow
Treatment with lomerizine increases interictal regional cerebral blood flow and may reduce migraine in chronic migraineurs.
FDA Reviews Biologics License Application for Novel Migraine Prevention Treatment
The Food and Drug Administration has accepted a Biologics License Application for the investigational migraine prevention treatment, galcanezumab.
Expert’s Insights Into Coverage Gap for Cluster Headache Oxygen Therapy
A recently published article exposes a gaping hole in the access to an effective first-line therapy for a portion of patients with cluster headache in the United States.
Patent Foramen Ovale Closure for Migraine: Weighing Risks and Benefits
There is a suggested link between migraine and the presence of patent foramen ovale, with the suggestion that PFO closure surgery might be a preventative measure against future migraine attacks, but what are the consequences?
Next post in Migraine & Headache
